A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy Participants

This is a phase 1, open‐label (all people know the identity of the intervention), randomized
(study medication is assigned by chance), parallel‐group, sequential study in healthy adult
participants to characterize the single-dose pharmacokinetics (PK) of rilpivirine (RPV) after
intramuscular (IM) injection of RPV LA nanosuspensions with different particle size
distributions (PSD), in healthy adult participants. A total of 110 healthy adult participants
will be enrolled in this study. The study will consist of 2 treatment sessions in a fixed
sequential order: Session 1- all participants will receive a single oral dose of rilpivirine
25 milligram (mg) as oral immediate release solution on Day 1; Session 2- the participants
will be randomized in session 2 on Day 1 in a 1:1:1:1:1 ratio to Treatments A, B, C, D and E.
Each treatment group will receive a single IM injection of RPV LA on Day 1 of session 2.
Session 1 and 2 will be separated by a washout period of at least 14 days. The total study
duration for each participant will be approximately 9.5 months. Safety will be monitored
throughout the study.

Inclusion Criteria:

- Participant must be willing and able to adhere to the prohibitions and restrictions
specified in this protocol

- Contraceptive use by men or women should be consistent with local regulations
regarding the use of contraceptive methods for participants participating in clinical
studies

- A female participant of childbearing potential must have a negative serum beta-human
chorionic gonadotropin test at screening and on Day -1 of each session

- For the duration of the study and for at least 6 months after intramuscular (IM)
injection of rilpivirine long-acting parenteral formulation (RPV LA) (or 1 month after
administration of rilpivirine (RPV) oral solution for participants who discontinue
after Session 1), male and female participants must agree to practice effective
methods of contraception, and must agree not to donate sperm (males)/eggs (ova,
oocytes; for females) for the purposes of assisted reproduction

- Participant must be non-smoking for at least 3 months prior to screening

Exclusion Criteria:

- Female participant who is breastfeeding at screening

- Participant with a history of any illness that, in the opinion of the investigator,
might confound the results of the study or pose an additional risk in administering
study drug to the participant or that could prevent, limit or confound the protocol
specified assessments. This may include, but is not limited to, renal dysfunction,
significant cardiac, vascular, pulmonary, gastrointestinal (such as significant
diarrhea, gastric stasis, or constipation that in the investigator's opinion could
influence drug absorption or bioavailability), endocrine, neurologic, hematologic,
rheumatologic, psychiatric, neoplastic, or metabolic disturbances

- Participant has a history of clinically relevant arrhythmias or history of risk
factors for Torsade de Pointes (hypokalemia, family history of long QT)

- Participant has clinically relevant, currently active, or underlying gastrointestinal,
cardiovascular, nervous system, psychiatric, metabolic, renal, hepatic, respiratory,
inflammatory or infectious disease

- Participant has known allergies, hypersensitivity, or intolerance to RPV or its
excipients